Trending...
- Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
- Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
- Wall Street Is Missing This One: Cycurion (NAS DAQ: CYCU) Gets $7 Price Target While Trading at a Steep Discount
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - ncarol.com -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on ncarol.com
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on ncarol.com
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on ncarol.com
- Iranian-Born Engineer Mohsen Bahmani Introduces Propeller-Less Propulsion for Urban Air Mobility
- Aleen Inc. (C S E: ALEN.U) Advances Digital Wellness Vision with Streamlined Platform Navigation and Long-Term Growth Strategy
- RimbaMindaAI Officially Launches Version 3.0 Following Strategic Breakthrough in Malaysian Market Analysis
- Fed Rate Pause & Dow 50k: Irfan Zuyrel on Liquidity Shifts, Crypto Volatility, and the ASEAN Opportunity
- 20/20 Institute Launches Updated Vision Correction Procedures Page for Denver & Colorado Springs
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on ncarol.com
- OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
- New Children's Picture Book "Diwa of Mount Luntian" Focuses on Calm, Culture, and Connection for Today's Families
- Actor, Spokesperson Rio Rocket Featured in "Switch to AT&T" Campaign Showing How Customers Can BYOD and Keep Their Number
- The World's No.1 Superstar® Brings Disco Fever Back With New Global Single and Video "Disco Dancing"
- Boston Industrial Solutions' Natron® 512N Series UV LED Ink Achieves BPA Certification, Advancing Safe and Sustainable Digital Printing
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on ncarol.com
- Parkway Prosthodontics Achieves Breakthrough Full-Arch Reconstruction Case
- Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
- Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
- Costa Oil Named Primary Sponsor of Carson Ware for the United Rentals 300 at Daytona International Speedway
- From Gen Z to Gen Alpha: The One Ingredient That Matters More Than Ever in STEM
- HBMHCW Expande Infraestructura de Cumplimiento para Argentina mientras América Latina Supera $1.5 Billones en Volumen Cripto
- Elixia Rebrands as Empathx Research Marking a New Era in Patient-Centered Recruitment
- Norisia Launches AI Formulated Luxury Multivitamin to Transform Daily Wellness in the UK
- Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
- NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
- When Interpretation Becomes Conversation: Rethinking Engagement in the Museum Age
- Half of Finnish Online Gambling Expenditure Now Flows to Offshore Instant Casinos as License Applications Open March 1, 2026
- RTC Communications Completes Next Level Connect Fiber Expansion Bringing Multi-Gig Broadband to West Boggs Community
- EPP Pricing Platform announces leadership transition to support long-term growth and continuity
- Stolen Hearts: Reclaiming Your Child From Parental Alienation (narcissistic abuse)
- Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
- Regional Real Estate Powerhouse
- A Valentine's Experience at Project 1610
- Wall Street Is Missing This One: Cycurion (NAS DAQ: CYCU) Gets $7 Price Target While Trading at a Steep Discount
- Aries Industries Streamlines Sewer Inspection Process With Introduction of the LETS Sidewinder